Literature DB >> 27900754

Ezrin and moesin expression in canine and feline osteosarcoma.

Juraj Hlavaty1, Birgitt Wolfesberger2, Marlene Hauck3, Barbara Obermayer-Pietsch4, Andrea Fuchs-Baumgartinger5, Ingrid Miller6, Ingrid Walter1,7.   

Abstract

Biological features of canine osteosarcomas (OS) differ markedly from those found in feline and resemble more human osteosarcomas, in particular for their high rate of metastasis and poor prognosis. Ezrin, radixin and moesin are members of the ERM protein family and link the actin cytoskeleton with the cell membrane. Ezrin and moesin have been shown to be of prognostic significance in tumor progression due to their role in the metastatic process. The objective of this study was to analyze ezrin and moesin protein expression in a series of dog (n = 16) and cat (n = 8) osteosarcoma samples using immunohistochemistry and western blot techniques. We found that cat OS have a higher moesin expression compared to dog OS, however, the active phosphorylated forms of moesin and ezrin Tyr353 were more abundant in the dog samples. A statistically significant difference was found for the low and high immunohistochemical scores of ezrin and pan-phospho-ERM proteins between cat and dog. Although phospho-ezrin Thr567 was higher in feline OS, the membranous localization in dog OS samples indicates the presence of the biologically active form. Therefore, the observed differences in phosphorylated forms of ezrin and moesin status should be further studied to demonstrate if they are relevant for different biological behavior between dog and cat OS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27900754     DOI: 10.14670/HH-11-848

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  1 in total

1.  Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases.

Authors:  M Bartova; J Hlavaty; Y Tan; C Singer; K Pohlodek; J Luha; I Walter
Journal:  Clin Exp Metastasis       Date:  2017-06-17       Impact factor: 5.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.